Literature DB >> 33969355

Man with a rash.

Rajitha Reddy1, Wesley Eilbert1, Omar Diaz1.   

Abstract

Entities:  

Year:  2021        PMID: 33969355      PMCID: PMC8087920          DOI: 10.1002/emp2.12442

Source DB:  PubMed          Journal:  J Am Coll Emerg Physicians Open        ISSN: 2688-1152


× No keyword cloud information.

CASE PRESENTATION

A 57‐year‐old male kidney transplant recipient presented to the emergency department with a 4‐day history of a painless, non‐pruritic rash that was initially confined to the right anterolateral midchest and then seemed to spread to his thorax, extremities, and scalp. There was no history of fever or new medications or other exposures. On examination, his vital signs were normal. Multiple vesicular lesions on an erythematous base were clustered on the right anterolateral midchest wall (Figure 1). Similar vesicular lesions in various stages of healing were scattered diffusely on his thorax, extremities, and scalp (Figures 2 and 3).
FIGURE 1

Cluster of vesicular lesions on an erythematous base on the anterolateral chest wall

FIGURE 2

Scattered vesicular lesions on the chest and back

FIGURE 3

Scattered vesicular lesions on the scalp

Cluster of vesicular lesions on an erythematous base on the anterolateral chest wall Scattered vesicular lesions on the chest and back Scattered vesicular lesions on the scalp

DIAGNOSIS

Disseminated varicella zoster.

DISCUSSION

Disseminated varicella zoster has been defined by the occurrence of at least 20 vesicular lesions outside of the primary and immediately adjacent dermatomes affected by zoster. Immunocompromised individuals with impaired T cell immunity, including organ and hematopoietic stem cell transplant recipients, persons receiving immunosuppressive therapy, and patients with leukemia, lymphoma, or HIV infection, are at increased risk of developing herpes zoster and experiencing more severe disease. Approximately two‐thirds of adult renal transplant recipients with disseminated varicella zoster will develop visceral complications including disseminated intravascular coagulation, pneumonitis, hepatitis, pancreatitis, and meningoencephalitis. Adult renal transplant recipients with disseminated varicella zoster have a mortality rate of 17%. Treatment of disseminated varicella zoster in immunocompromised patients is with intravenous acyclovir. Our patient was treated empirically with intravenous acyclovir and admitted to the hospital. Polymerase chain reaction testing of a lesional swab later confirmed the presence of varicella zoster virus. Other diagnoses to consider in the patient with a diffuse vesicular rash include disseminated herpes simplex and viral exanthems, especially those caused by enteroviruses. , The lack of prominent mucosal involvement in this patient made those diagnoses less likely. The diagnosis of varicella zoster may be dismissed when the classic lesions are distributed outside of a dermatomal pattern. This diagnosis must always be kept in mind, especially in an immunocompromised patient.
  5 in total

1.  Herpes simplex virus infections in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.

Authors:  Dong H Lee; Richard A Zuckerman
Journal:  Clin Transplant       Date:  2019-04-11       Impact factor: 2.863

Review 2.  Disseminated varicella zoster virus infection in adult renal transplant recipients: outcome and risk factors.

Authors:  M Rommelaere; C Maréchal; J-C Yombi; E Goffin; N Kanaan
Journal:  Transplant Proc       Date:  2012-11       Impact factor: 1.066

Review 3.  Varicella zoster virus.

Authors:  M L McCrary; J Severson; S K Tyring
Journal:  J Am Acad Dermatol       Date:  1999-07       Impact factor: 11.527

Review 4.  Hand-foot-and-mouth disease: a new look at a classic viral rash.

Authors:  Christopher Nassef; Carolyn Ziemer; Dean S Morrell
Journal:  Curr Opin Pediatr       Date:  2015-08       Impact factor: 2.856

Review 5.  Clinical practice: Herpes zoster.

Authors:  Jeffrey I Cohen
Journal:  N Engl J Med       Date:  2013-07-18       Impact factor: 91.245

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.